AXSM

Axsome Therapeutics, Inc. | Cotação de Ações

Última atualização19/09/2025, 17:00:02

PreçoUS$ 115,95

Variação (dia)-US$ 2,68 (-2.26%)▼

Min. 52 SemanasUS$ 75,56

Máx. 52 SemanasUS$ 139,13

Capitalização de mercado--

Endereço: One World Trade Center, New York, NY, 10007

Telefone: 212 332 3241

Funcionários: 846

Axsome Therapeutics, Inc.AXSM

US$ 115,95

- 2,682,3%

19/09/2025 17:00:02

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 115,95

Valor de mercado--

AberturaUS$ 118,71

Preço máximoUS$ 118,77

Preço mínimoUS$ 115,76

VolumeUS$ 605 mil

Fechamento anteriorUS$ 118,63

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Ações relacionadas

Intra-Cellular Therapies, Inc.

ITCI ▲0.60% | US$ 126,80

TG Therapeutics, Inc.

TGTX ▲0.54% | US$ 30,09

Madrigal Pharmaceuticals, Inc.

MDGL ▲8.56% | US$ 302,21

Aurinia Pharmaceuticals Inc.

AUPH ▼0.17% | US$ 7,85

Apellis Pharmaceuticals, Inc.

APLS ▲0.40% | US$ 30,33

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.